[New agents in the treatment of leukemia and lymphoma].
D015250:Aclarubicin / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D006801:Humans; D007263:Infusions, Parenteral; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D009279:Naphthacenes; C011157:aclacinomycins; D003561:Cytarabine; D015250:Aclarubicin; D004317:Doxorubicin; C015019:enocitabine; C027260:pirarubicin